• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Which New Combination for Metastatic Renal Cell Cancer?

  • — 12 Nov, 2018
Which New Combination for Metastatic Renal Cell Cancer?
Which Molecular Drug Combinations for Renal Cancer?
Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
Which New Combination for Metastatic Renal Cell Cancer?
Which New Combination for Metastatic Renal Cell Cancer?
00:00 / 9 minutes
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed

Subscribe: Apple Podcasts | Spotify | Stitcher

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two different programmed death ligand 1 (PD-L1) targeted immunotherapies together—and also with therapies combining immunotherapy with tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor (VEGF).

Although such combinations had improved progression free survival (PFS) and even promised prolongation of overall survival (OS) the lack of comparisons between them left clinicians with little guidance—other than toxicity profiles—upon which to individualize treatment for their patients.

No biomarkers

“Unfortunately we don’t have good biomarkers that would help us selecting patients who would benefit either from immunotherapy alone, VEGF targeting agents alone, or the combination. So we have to look at the safety profiles of the combinations that we have right now—either the combinations with immunotherapies (alone) or the combination of a VEGF targeting agent and an anti PD-L1 drug—and see what would be the best for the patient that you have in front of you,” the Audio Journal of Oncology heard from John B.A.G. Haanen MD PhD, Chief Scientific Officer Immunotherapy and Consultant Medical Oncologist in the Division of Medical Oncology and Immunotherapy at the Netherlands Cancer Institute in Amsterdam.

 

You may also like...

  • Oropharyngeal Carcinoma: Better Outlook From Human Papilloma Virus-Directed Therapies— Different Patient Characteristics, New Therapeutic Opportunities Oropharyngeal Carcinoma: Better Outlook From Human Papilloma Virus-Directed Therapies— Different Patient Characteristics, New Therapeutic Opportunities 15 Apr, 2009
  • Audio Journal of Hematologic Malignancy Special Edition 2005 Audio Journal of Hematologic Malignancy Special Edition 2005 8 Dec, 2005
  • Richard Coker ‘Flu Pandemic Preparedness: Research Identifies Effective Measures For Saving Lives 6 Apr, 2012
  • For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival 28 Sep, 2009
  • Previous story Two Drug Combination Doubled Kidney Cancer Progression Free Survival
  • Next story Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with Chronic…
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
  • Home
  • Oncology
  • AJO
  • Which New Combination for Metastatic Renal Cell Cancer?

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.